# BDgene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bdgene

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.bdgenetherapeutics.com
- Total disclosed funding: $37M
- Latest round: Series C (Mar 31, 2026)
- Investors on record: 13

## About

Based in Hangzhou, China and founded in 2018, Hangzhou BDgene Therapeutics Co. Ltd., dba BDgene, operates as a biotechnology company which focuses on drug development for gene therapy. The company's founder, Yujia Cai, is a member of the Systems Biomedicine Committee of the Chinese Society of Bioengineering. BDgene was initially headquartered in Shanghai but later relocated to Hangzhou in March 2026; the Shanghai base, however, still operates as a R&D center of the company.

In March 2026, BDgene closed a round of series C funding led by Efung Capital with participation from Hangzhou Gongshu State Investment Industry Development and Hongcheng Investment Management.

Leveraging its two main delivery platforms, viral-like vector BD-VLP platform and lentiviral vector BD-Lenti platform and utilizing AI (Artificial Intelligence), BDgence has developed multiple pipeline products for treating tumor, cancer, Parkinson's disease, genital herpes, etc., some of which, including HSK-BD111, an antiviral gene-editing drug for the treatment of viral keratitis, and Thalassemia-BD211 for the treatment of transfusion-dependent ß-thalassemia, have reached final phases of clinical trials.

The company generates revenue from developing cell and gene therapy drugs.

## Funding rounds

- Series C, Mar 31, 2026 — Efung Capital, Hongcheng Investment Management, Hangzhou Gongshu State Investment Industry Development
- Series B, Jun 27, 2023, $28M — Hermed Capital, Lapam Capital, Sunland Capital, Penglai Capital, Sprinvest
- Series A, Apr 12, 2021, $9.2M — Emerging Technology Partners, T-Capital, Zhuhai Longmen Capital Management, Innoangel Fund, Ennovation Ventures

## Investors

- Emerging Technology Partners (https://capitalatlas.ai/funds/emerging-technology-partners) — Series A
- T-Capital — Series A
- Zhuhai Longmen Capital Management (https://capitalatlas.ai/funds/zhuhai-longmen-capital-management) — Series A
- Innoangel Fund (https://capitalatlas.ai/funds/innoangel-fund) — Series A
- Ennovation Ventures (https://capitalatlas.ai/funds/ennovation-ventures) — Series A
- Hermed Capital (https://capitalatlas.ai/funds/hermed-capital) — Series B
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series B
- Sunland Capital — Series B
- Penglai Capital — Series B
- Sprinvest — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series C
- Hongcheng Investment Management (https://capitalatlas.ai/funds/hongcheng-investment-management) — Series C
- Hangzhou Gongshu State Investment Industry Development — Series C